



A**B**





LIM consensus: **CXXCX16–23HXXCXXCXXCXXC16–21CX2–3(C, H, or D).**



Paxillin Lim1	326	CGA C KKPI-AGQVVT----AMGKTW H PE H FV C TH C QEEIG-SRNFFERDGQ-PY C EKD	376
Paxillin Lim2	385	CYY C NGPI-LDKVVT----ALDRTW H PE H FF C AQ C GVFFG-PEGFHEKD G K-AY C RKD	435
Paxillin Lim3	444	CGG C ARAI-LENYIS----ALNTL W PE C FV C REC C FTPFI-NGSFFEH D GQ-PY C EV H	494
Paxillin Lim4	503	CSG C QKPI-TGRCIT----AMGKKF H PE H FV C AF C LKQLN-KGTFKEQNDK-PY C QNC	553
SpPx11 Lim1	258	CHSCGGSLRAGRIIS----ASGKKL H PQ C FK C DT C SQNLE-HVGFYREG K -FY C HL D	309
SpPx11 Lim2	318	CKH C KTP I -EDQAVH----INNDWF H EN H F C AG C SEVFNVNIP C IYRDDL-YW C Q T C	369
SpPx11 Lim3	378	CKK C RKPI-LGISVK----GSDGEY H SQCWT C GACNALLG-DEGYFMI E NT-PI C R P C	428
ScPx11 Lim1	556	CRACGLEVTGKRMFSKKENELSG Q W H REC C FK C IE C GU K FNKH V PCY I LG D E-PY C Q K H	612
ScPx11 Lim2	621	CKV C SNFI-EGECLE---NDKVERF H V D CL N CFL C KTAIT--NDYYIFNGE I PL C GN H	672
	*	*	*
	:	:	*
	.	*	*
	*	:	*
	*	*	*
	*	:	*
	*	*	*
	*	*	*

Supplementary Figure 1




Supplementary Figure 2


A**B****C****D****Supplementary Figure 3**



Supplementary Figure 4



Supplementary Figure 5



Supplementary Figure 6